Minoxidil is a vasodilator drug originally developed in the late 1950s and introduced in the 1970s for the treatment of severe hypertension. Its history is notable for the unexpected discovery of hair growth as a side effect, which later led to its repurposing as a topical treatment for androgenetic alopecia (pattern hair loss). Minoxidil works by opening ATP-sensitive potassium channels in vascular smooth muscle, leading to vasodilation and improved blood flow. Over time, it became widely used in dermatology as a topical solution or foam to stimulate hair regrowth, with its clinical use guided by dose-dependent effects and potential systemic absorption in higher exposures.
BRAND NAMES
Rogaine – the most widely recognized brand for androgenetic alopecia (hair loss treatment)
Regaine – commonly used international brand for topical hair regrowth
Loniten – oral formulation used for severe or resistant hypertension.
MECHANISM OF ACTION
Minoxidil is a potassium channel opener that acts on vascular smooth muscle cells. It opens ATP-sensitive potassium channels, causing hyperpolarization of the cell membrane and resulting in relaxation of arteriolar smooth muscle. This leads to peripheral vasodilation and reduced vascular resistance. In hair follicles, minoxidil is believed to enhance blood flow to dermal papilla cells, prolong the anagen (growth) phase, and increase follicular size, promoting hair regrowth.
PHARMACOKINETICS
Absorption:
Topical minoxidil is minimally absorbed systemically, while oral minoxidil is well absorbed from the gastrointestinal tract. Food does not significantly affect absorption of oral formulations.
Distribution:
Minoxidil is moderately distributed in body tissues. Oral administration allows distribution to vascular tissues and hair follicles. Plasma protein binding is relatively low.
Metabolism:
It is metabolized primarily in the liver to its active form, minoxidil sulfate, which is responsible for its pharmacological effects.
Elimination:
Excretion occurs mainly via the kidneys, predominantly as metabolites. The drug has a short plasma half-life, but biological effects persist due to active metabolite formation.
PHARMACODYNAMICS
Minoxidil produces direct arteriolar vasodilation by opening potassium channels in smooth muscle, reducing peripheral resistance and lowering blood pressure (systemic use). In hair follicles, it stimulates dermal papilla activity, increases follicular size, and promotes transition of hair follicles into the growth (anagen) phase, resulting in increased hair density.
ADMINISTRATION
Minoxidil is available in topical and oral forms. Topical formulations (solution or foam) are applied directly to the scalp for hair loss treatment. Oral tablets are used for severe hypertension or low-dose off-label hair restoration under medical supervision.
DOSAGE AND STRENGTH
Minoxidil is available in both topical and oral forms with varying strengths depending on its use. For hair loss treatment, topical minoxidil is commonly available as 2% and 5% solutions or foam formulations, applied directly to the affected scalp once or twice daily on a continuous basis for sustained results. In hypertension management, oral minoxidil tablets are used in carefully titrated doses under strict medical supervision, starting from low doses and adjusted according to blood pressure response.
DRUG INTERACTIONS
Minoxidil may enhance the effects of antihypertensive medications, leading to additive hypotension. It is often combined with beta-blockers or diuretics to manage reflex tachycardia and fluid retention. Caution is required when used with other vasodilators.
FOOD INTERACTIONS
Food has minimal effect on absorption of oral minoxidil. Topical formulations are unaffected by diet.
CONTRAINDICATIONS
Minoxidil is contraindicated in patients with pheochromocytoma (untreated) and should be used cautiously in individuals with significant cardiovascular disease due to risk of tachycardia and fluid retention.
SIDE EFFECTS
Hypertrichosis (excess hair growth on face, arms, or body)
Scalp irritation (itching, dryness, redness, flaking – mainly topical use)
Headache
Dizziness or lightheadedness
Tachycardia (increased heart rate)
Fluid retention (swelling of ankles, hands, or face)
Weight gain due to fluid accumulation
Orthostatic hypotension (drop in blood pressure on standing)
Chest discomfort or palpitations (rare but serious, mainly oral use)
Temporary hair shedding at the start of treatment (shedding phase)
OVER DOSAGE
Overdose of Minoxidil is primarily related to its strong systemic vasodilatory effects. Clinical features may include severe hypotension, reflex tachycardia, dizziness, syncope, and fluid retention. In more serious cases, patients may develop shock, chest pain due to reduced coronary perfusion, or signs of heart failure from fluid overload.
TOXICITY
Toxicity of Minoxidil is mainly due to excessive vasodilation, leading to severe hypotension, reflex tachycardia, fluid overload, and possible cardiovascular collapse in extreme cases. Management is supportive, including cardiovascular monitoring, IV fluids if needed, and vasopressors for severe hypotension.
